RxDoctor Payments DataLook up a doctor →

Stephen Sides, DO

Rheumatology · Jefferson City, MONPI 1366428914

Payments from drug & device makers

$50,103in general payments, 2019–2025

Across 419 payments — averaging $119.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$39K
  • Janssen Scientific Affairs, LLC$6K
  • Amgen$1K
  • AbbVie$980
  • Johnson & Johnson$778
  • AstraZeneca$540
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$4,27137%
  • Travel & lodging$2,05418%
  • Food & beverage$4,95243%
  • Education$1742%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,103 in reported general payments places this provider in the 85th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$4,849,882
Medicare patients
790
Services billed
242,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab92$986,762
Enbrel SureclickEtanercept107$927,674
Humira(Cf)Adalimumab29$337,863
Cosentyx Sensoready (2 Pens)Secukinumab44$334,718
Xeljanz XrTofacitinib Citrate41$333,601
OtezlaApremilast53$294,464
Orencia ClickjectAbatacept41$285,407
EnbrelEtanercept20$252,855
TremfyaGuselkumab17$244,302
Humira PenAdalimumab16$116,483
Hydroxychloroquine Sulfate1,043$35,029
MethotrexateMethotrexate Sodium937$25,355
AvsolaInfliximab-Axxq13$20,671
OtrexupMethotrexate/Pf13$9,690
Mycophenolate Mofetil67$7,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel, Avsola$1,161$567,99086 claims
AbbVieHumira(Cf)$980$337,86329 claims
Johnson & JohnsonTremfya$778$244,30217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Jefferson City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →